We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA cited Reliance Life Sciences for a long list of deficiencies observed during an inspection of the API manufacturer’s facility in Navi Mumbai in December. Read More
The FDA hit Eau Zone Huiles Et Fragrances with a Form 483 after an inspection determined the OTC manufacturer had numerous deficiencies at its Montreal, Quebec facility, including cleaning, testing and drug storage issues. Read More
For products placed on the market as of the UK’s withdrawal date, batch release cannot be carried out by a laboratory located in the UK, the agency said. Read More
The two claim the board continues to commit violations of the Securities and Exchange Act by intentionally publishing false or misleading information. Read More
The FDA issued a warning letter to Ami Cosmetics in Soeul, South Korea, saying the over-the-counter drugmaker had contradictory information in its labeling and its electronic listing in the FDA’s National Drug Code directory. Read More
The FDA cited Reliance Life Sciences for a long list of deficiencies observed during an inspection of the API manufacturer’s facility in Navi Mumbai in December. Read More
The FDA hit Eau Zone Huiles Et Fragrances with a Form 483 after an inspection determined the OTC manufacturer had numerous deficiencies at its Montreal, Quebec facility, including cleaning, testing and drug storage issues. Read More